Abstract | BACKGROUND: Oral budesonide 9 mg/day represents first-line treatment of mild-to-moderately active ileocolonic Crohn's disease. However, there is no precise recommendation for budesonide dosing due to lack of comparative data. A once-daily (OD) 9 mg dose may improve adherence and thereby efficacy. METHODS: An eight-week, double-blind, double-dummy randomised trial compared budesonide 9 mg OD versus 3mg three-times daily (TID) in patients with mild-to-moderately active ileocolonic Crohn's disease. Primary endpoint was clinical remission defined as CDAI <150 at week 8 (last observation carried forward). RESULTS: The final intent-to-treat population comprised 471 patients (238 [9 mg OD], 233 [3 mg TID]). The confirmatory population for the primary endpoint analysis was the interim per protocol population (n=377; 188 [9 mg OD], 189 [3mg TID]), in which the primary endpoint was statistically non-inferior with budesonide 9 mg OD versus 3 mg TID. Clinical remission was achieved in 71.3% versus 75.1%, a difference of -3.9% (95% CI [-14.6%; 6.4%]; p=0.020 for non-inferiority). The mean (SD) time to remission was 21.9 (13.8) days versus 21.4 (14.6) days with budesonide 9 mg OD versus 3 mg TID, respectively. In a subpopulation of 122 patients with baseline SES-CD ulcer score ≥1, complete mucosal healing occurred in 32.8% (21/64) on 9 mg OD and 41.4% (24/58) on 3mg TID; deep remission (mucosal healing and clinical remission) was observed in 26.6% (17/64) and 32.8% (19/58) of patients, respectively. Treatment-emergent suspected adverse drug reactions were reported in 4.6% of 9 mg OD and 4.7% of 3 mg TID patients. CONCLUSIONS:
Budesonide at the recommended dose of 9 mg/day can be administered OD without impaired efficacy and safety compared to 3mg TID dosing in mild-to-moderately active Crohn's disease.
|
Authors | Axel Dignass, Simeon Stoynov, Andrey E Dorofeyev, Galina A Grigorieva, Eva Tomsová, István Altorjay, Daniel Tuculanu, Ivan Bunganič, Juris Pokrotnieks, Limas Kupčinskas, Karin Dilger, Roland Greinwald, Ralph Mueller, International Budenofalk Study Group |
Journal | Journal of Crohn's & colitis
(J Crohns Colitis)
Vol. 8
Issue 9
Pg. 970-80
(Sep 2014)
ISSN: 1876-4479 [Electronic] England |
PMID | 24534142
(Publication Type: Clinical Trial, Phase III, Journal Article, Multicenter Study, Randomized Controlled Trial)
|
Copyright | Copyright © 2014 European Crohn's and Colitis Organisation. Published by Elsevier B.V. All rights reserved. |
Chemical References |
- Glucocorticoids
- Budesonide
|
Topics |
- Administration, Oral
- Adolescent
- Adult
- Aged
- Budesonide
(administration & dosage)
- Crohn Disease
(drug therapy, pathology)
- Dose-Response Relationship, Drug
- Double-Blind Method
- Drug Administration Schedule
- Endoscopy, Gastrointestinal
- Female
- Follow-Up Studies
- Glucocorticoids
(administration & dosage)
- Humans
- Intestinal Mucosa
(pathology)
- Male
- Middle Aged
- Patient Compliance
- Prospective Studies
- Remission Induction
- Treatment Outcome
- Young Adult
|